Tazemetostat as Third-line and Beyond Therapy for FL

Opinion
Video

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Related Videos
Carrie L. Kitko, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Lori A. Leslie, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Lori A. Leslie, MD